Nickel/Photoredox‐Catalyzed Asymmetric Reductive Cross‐Coupling of Racemic α‐Chloro Esters with Aryl Iodides
作者:Haixing Guan、Qianwen Zhang、Patrick J. Walsh、Jianyou Mao
DOI:10.1002/anie.201914175
日期:2020.3.23
A unique nickel/organic photoredox co-catalyzed asymmetricreductive cross-coupling between α-chloro esters and aryl iodides is developed. This cross-electrophile coupling reaction employs an organic reductant (Hantzschester), whereas most reductive cross-coupling reactions use stoichiometric metals. A diverse array of valuable α-aryl esters is formed under these conditions with high enantioselectivities
[EN] WNT PATHWAY MODULATORS<br/>[FR] MODULATEURS DE LA VOIE WNT
申请人:AGENCY SCIENCE TECH & RES
公开号:WO2015094119A1
公开(公告)日:2015-06-25
The present invention relates to dihydropyrazolo[l,5-a]pyrimidine compounds of formula I, defined herein, as WNT pathways modulators, processes for making them, and pharmaceutical compositions comprising them. Methods of treatment of conditions mediated by WNT pathway signalling including cancer, fibrosis, stem cell and diabetic retinopathy, rheumatoid arthritis, psoriasis and myocardial infarction, comprising the compounds of formula I are also provided.
Synthesis of the Precursor of Anti-Inflammatory Agents by Cross-Coupling Using Electrogenerated Highly Reactive Zinc
作者:Masao Tokuda、Aishah A. Jalil、Nobuhito Kurono
DOI:10.1055/s-2002-35978
日期:——
Highlyreactive zine metal was readily prepared by electrolysis of a DMF solution containing naphthalene and a supporting electrolyte in a one-compartment cell fitted with a platinum cathode and a zinc anode. This reactivezinc was used for efficient transformation of ethyl 2-bromoacrylate into the corresponding organozinc compound, which was reacted with various aryl iodides in the presence of palladium
The invention relates to cinnamic acid derivatives of formula S
wherein the radicals have the meaning indicated in claim 1,
to a process for their preparation and their use as self assembling photoalignment agent in liquid crystal mixtures. The invention further relates to a process for the fabrication of a liquid crystal (LC) display device with homogeneous alignment by photoaligning a liquid crystal mixture with positive or negative dielectric anisotropy comprising one or more compounds of formula S and optionally a polymerizable compound, to the liquid crystal mixture comprising the self assembling photoaligning agent and optionally the polymerizable compound and to the LC display produced by said process.
本发明涉及式 S 的肉桂酸衍生物
其中的基团具有权利要求 1 所述的含义、
本发明还涉及一种制备方法,以及将其用作液晶混合物中的自组装光配向剂。本发明还涉及一种通过对包含一种或多种式 S 化合物(可选)和一种可聚合化合物 的具有正或负介电各向异性的液晶混合物进行光配位来制造具有均匀配位的液晶显示装 置的工艺,涉及包含自组装光配位剂(可选)和可聚合化合物的液晶混合物,以及通 过上述工艺制造的液晶显示器。
[EN] SELECTIVE MMP INHIBITORS<br/>[FR] INHIBITEURS SÉLECTIFS DE MMP
申请人:SYMPHONY EVOLUTION INC
公开号:WO2014028334A1
公开(公告)日:2014-02-20
Described are methods for treating diseases by use of agents that selectively inhibit human metalloproteinases (MMP), such as MMP-9 and MMP-2, while optionally sparing MMP-1. Prevention of atherosclerotic plaque development and rupture and/or carotid arterial plaque development and rupture, by MMP inhibition can reduce the adverse consequences of plaque development and rupture including thromboembolism, stroke, myocardial infarction and acute coronary syndromes.